Pharmaceutical Technology, January 2024

Revolutionary therapies restructure pharmaceutical manufacturing.

European bio/pharma companies have no choice but to invest and adapt to the evolving industry needs.

There are positive indications for future growth.

A thoughtfully constructed QRM Master Plan translates the strategy and enables a risk-based approach.

Novel molecular glues are transforming targeted protein degradation.

Buffers, stabilizers, and cryoprotectants play major roles in cell therapy formulations.

Designers adopt value-added features, different materials, and enhanced coding technologies.

UK scientists are once again able to participate in the Horizon European research programme thanks to a deal struck in 2023.

Analytical methods and tools play a pivotal role in cleaning validation.

The EHDS aims to increase access to health data, but how will it impact pharma?

Clarivate has released its 2024 Drugs to Watch report, highlighting 13 therapies with great potential.

GSI shortages result from how hospitals buy GSI drugs, and the underinvestment in manufacturing operations that follow.

Reviewing regulatory documents, such as 483 forms and Warning Letters, can aid in determining a facility’s inspection readiness, says Siegfried Schmitt, vice president, Technical at Parexel.

Galbraith Laboratories, a Bureau Veritas Company, offers a full range of analytical services for pharma, from R&D to final release testing.

ROSS Mixers, a provider of US-designed and manufactured mixing equipment, offers a Trial Rental Program, giving process managers an opportunity to optimize R&D projects before committing to a substantial investment.